ABSTRACT NO. | ABSTRACT TITLE | ABSTRACT TOPIC | SALUTATION | FIRST NAME | LAST NAME |
---|---|---|---|---|---|
ASVAC 1001 | Persistence of protective anti polio antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, Alum adjuvanted dose sparing inactivated polio vaccine |
Polio | Dr. | Hans- Henrik | Kristensen |
ASVAC 1003 | Vaccination Hesitancy On Childhood Vaccinations During COVID-19 Pandemic In A Tertiary Hospital: A Cross-Sectional Study |
Vaccines in specific settings | Dr. | Jennica Alexis | Algas |
ASVAC 1013 | Knowledge and Attitudes Perceived by Junior High School Students on COVID-19 vaccines in a Private and a Public High School in Tarlac City |
Vaccines in specific settings | Ms. | Maria Rosario | Gaspar |
ASVAC 1017 | Evaluating the immunogenicity, efficacy, and safety of TAK-003 by age group: an analysis of the DEN-301 phase 3 clinical trial |
Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya | Dr. | Jennifer | Feliciano |
ASVAC 1020 | COVID-19 Vaccine Effectiveness Research in Southeast Asia: Current Capability Using Secondary Data |
Disease-specific vaccines | Dr. | Anne-Frieda | Taurel |
ASVAC 1021 | Presenteeism: The Reality to be Discussed With COVID-19 Vaccine Recipients |
Respiratory viruses e.g Influenza, Respiratory Syncytial virus | Dr. | Seth | Toback |
ASVAC 1024 | Safety and immunogenicity of a bivalent omicron BA.4/BA.5 vaccine against COVID-19 |
Disease-specific vaccines | Dr. | Spyros | Chalkias |
ASVAC 1025 | Burden and Impact of Reactogenicity Among United States and Canadian Adults Receiving COVID-19 Vaccines: Vaccine Impact on Productivity (VIP) Study |
Respiratory viruses e.g Influenza, Respiratory Syncytial virus | Dr. | Matthew | Rosculp |
ASVAC 1026 | How Much of a Burden Is Vaccine-Related Reactogenicity? Results from a 6-Day Symptom Diary Among United States and Canadian Adults Receiving COVID-19 Vaccines |
Respiratory viruses e.g Influenza, Respiratory Syncytial virus | Dr. | Matthew | Rosculp |
ASVAC 1030 | Remaining Lifetime Burden of Herpes Zosters and Public Health Impact of Adjuvanted Recombinant Zoster Vaccine among Adults ≥50 Years in Five Countries in Southeast Asia |
Evidenced-based introduction of new vaccines | Dr. | Ru | Han |
ASVAC 1033 | TAK-003 dengue vaccine clinical experience: an integrated analysis of safety data by baseline serostatus |
Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya | Dr. | Steven | Stockton |
ASVAC 1034 | The indirect costs and burden of vaccine preventable cancers mortality in Asia-Pacific countries |
Disease-specific vaccines | Dr. | Rosculp | Bencina |
ASVAC 1035 | An open-label, phase 2 study evaluating cell-mediated immune response and safety of a tetravalent dengue vaccine in children and adolescents aged 4–16 years |
Mosquito-borne viruses e.g Dengue, Japanese encephalitis, Zika, Malaria and Chikungunya | Dr. | Sanja | Mandaric |
ASVAC 1037 | A case of invasive pneumococcal disease by non-vaccine serotype 15C. |
Disease-specific vaccines | Dr. | Shu Ting Tammie | Seethor |
ASVAC 1038 | MesVaccins.net: A New Digital Vaccination Card to Empower People and Healthcare Professionals |
Monitoring and surveillance | Prof. | Jean-Louis | Koeck |
ASVAC 1039 | Influenza Associated Acute Necrotizing Encephalopathy (ANEC) and the role of Influenza Vaccination: A Case Study |
Respiratory viruses e.g Influenza, Respiratory Syncytial virus | Dr. | Mark | Goh |
ASVAC 1040 | Salmonella-delivered COBRA-HA1 antigen derived from H1N1 hemagglutinin sequences elicits broad-spectrum protection against influenza A subtypes |
Respiratory viruses e.g Influenza, Respiratory Syncytial virus | Prof. | John Hwa | Lee |
ASVAC 1041 | Novel pro-and eukaryotic expression plasmid expressing omicron antigens delivered via Salmonella elicited MHC class I and II based protective immunity |
Vaccines in development | Prof. | John Hwa | Lee |
ASVAC 1042 | Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster |
Vaccines in development | Prof. | John Hwa | Lee |
ASVAC 1044 | Relative effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S vaccines in adults at higher risk for severe COVID-19 outcomes |
Disease-specific vaccines | Dr. | Van Hung | Nguyen |
ASVAC 1046 | Capabilities, Post-Coup And Cataclysm; covid-19 Vaccine Acceptance And Its Determinants Among Myanmar Migrant Workers In Southern Thailand, Myanmar’s Responses To Covid-19 |
Targeted vaccination strategies | Dr. | Aung Tan | Oo |
ASVAC 1047 | Factors Associated with Death in Adult COVID-19 Patients Admitted to Two Referral Hospitals in the Philippines |
Disease-specific vaccines | Dr. | Jude Raphael | Lo |
ASVAC 1048 | Assessment Of Maternal Knowledge, Attitudes, And Perceptions On HPV Vaccination For Females Aged 9-17 Years In Calamba City, Laguna |
Vaccines in specific settings | Ms. | Maria Teresa | Bsilides |
ASVAC 1052 | Interchangeability of Pneumococcal Conjugate Vaccines in Children – Systematic Review and Meta Analysis |
Vaccine Implementation | Dr. | John Andrew | Caposano |
ASVAC 1055 | Effect of Web-based Short Message Service (SMS) Reminders on Vaccination Coverage and Timeliness of Routine Immunizations Among Infants in Baguio City: A Randomized Controlled Trial |
Targeted vaccination strategies | Dr. | Karla | Rigos |
ASVAC 1056 | Australia’s rotavirus immunisation program: impact on acute gastroenteritis hospitalisations over 13 years |
Enteric Vaccines e.g. Cholera, Typhoid and Rotavirus | Dr. | Aditi | Dey |
ASVAC 1057 | Acceptance Of COVID-19 Vaccination Among Children Who Were Eligible to Receive CYD-TDV In 2017 In Cebu, Philippines |
Vaccines in specific settings | Ms. | Anna Maureen | Cuachin |
ASVAC 1058 | Do you speak vaccines? Proposal for a structured global terminology on vaccines |
Monitoring and surveillance | Prof. | Jean-Louis | Koeck |
ASVAC 1059 | Standardization and Harmonization of COVID-19 Case and Vaccination Data in Selected Philippine Cohorts |
Monitoring and surveillance | Mr. | Arturo Jr. | Ongkeko |
ASVAC 1060 | The Philippine COVID-19 Vaccine Effectiveness Project |
Vaccines in specific settings | Dr. | Regina | Berba |